AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 80 filers reported holding AVADEL PHARMACEUTICALS PLC in Q1 2018. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,682,835 | -25.3% | 163,382 | +19.5% | 0.06% | -28.0% |
| Q2 2023 | $2,254,019 | +36.0% | 136,773 | -24.4% | 0.08% | +22.4% |
| Q1 2023 | $1,657,960 | +211.9% | 181,000 | +143.8% | 0.07% | +157.7% |
| Q4 2022 | $531,630 | -65.9% | 74,250 | -68.2% | 0.03% | -67.1% |
| Q4 2020 | $1,561,000 | -24.2% | 233,747 | -42.8% | 0.08% | -43.2% |
| Q3 2020 | $2,059,000 | -60.7% | 408,625 | -36.9% | 0.14% | -57.1% |
| Q2 2020 | $5,233,000 | +729.3% | 647,708 | +741.2% | 0.32% | +881.8% |
| Q4 2017 | $631,000 | -84.7% | 77,000 | -80.3% | 0.03% | -84.1% |
| Q3 2017 | $4,114,000 | -44.0% | 391,839 | -41.2% | 0.21% | -47.7% |
| Q2 2017 | $7,349,000 | -23.9% | 666,316 | -33.2% | 0.40% | -16.6% |
| Q1 2017 | $9,651,000 | – | 997,000 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
| COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
| GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
| Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
| Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
| Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
| Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
| Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
| RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
| FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |